Artikel
Patient-Reported Outcome Measures (PROMs) in Dermatology
Interview by DermTalks
DermTalks is a project led with a board of dermatologists and intended to address current challenges, data gaps and emerging trends in dermatology across North-European countries.
Speaker: Prof. Mette Deleuran, Associate Professor and Chair of the Department of Dermatology and Venereology, Aarhus University Hospital, Denmark.
Autoimmune Type 1 Diabetes
The Type 1 Diabetes (T1D) field is evolving.
Recognition of the presymptomatic stages in T1D is growing.1-4
The clinical benefits of early detection of T1D are being highlighted.3-4 Programmes focusing on early detection through testing and screening for presymptomatic autoimmune T1D are increasingly offered to risk populations and the general population.1,2
A Paradigm Shift in Early Detection of Autoimmune Type 1 Diabetes
Autoimmune Type 1 diabetes (T1D) is undergoing a fundamental transformation in how the medical community approaches diagnosis and care.
Optimér behandlingen af svær astma: Vælg målrettede biologiske behandlinger frem for vedligeholdelsesbehandling med orale kortikosteroider
What is PRALUENT®(alirocumab)?
PRALUENT: a PCSK9i that ticks all the boxes1–4 PRALUENT is a PCSK9i that reduces the levels of LDL-C in the blood.2 It is a fully human IgG1 monoclonal antibody that works by inhibiting the binding of PCSK9 to LDL- receptors. As a result, PRALUENT increases the number of LDL-receptors available to clear LDL, thereby lowering LDL-C levels.2 Elevated LDL-C levels have been significantly associated with cardiovascular disease such as heart attacks and strokes.1
